Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: declining revenue and gross margin, but with optimistic guidance on revenue recovery and cash flow improvements. The company's strategic initiatives, such as international expansion and new product launches, are promising. However, the absence of forward guidance and unresolved supply chain issues are concerning. The Q&A section highlights management's confidence in overcoming current challenges, yet lacks specific guidance, creating uncertainty. Thus, the stock price is likely to remain stable, with potential for moderate fluctuations as the market digests these mixed signals.
Key Financial Performance
Revenue for Q1 2026 $3.9 million compared to $5 million in Q1 2025, a decline primarily driven by lower AlterG shipments due to temporary supply chain and sourcing constraints associated with working capital limitations and the final stage of manufacturing transition activities.
ReWalk personal exoskeleton revenue $1.6 million, an 11% year-over-year increase, reflecting continued progress in reimbursement coverage, channel expansion, and international sales.
Gross margin for Q1 2026 34.2% compared to 42.2% in Q1 2025, a decrease due to lower manufacturing absorption from reduced production volumes, higher freight and tariff expenses, and unfavorable foreign currency exchange rate movements.
Total operating expenses $11.7 million, an increase primarily due to a one-time noncash R&D expense of approximately $4.9 million related to acquired intellectual property assets in connection with the Oratech transaction.
Adjusted operating expenses (non-GAAP) $5.9 million, a 12% decline compared to $6.8 million in Q1 2025, driven by improved productivity across sales and marketing operations, lower reimbursement-related costs, and reduced R&D spending following the completion of major development programs.
GAAP operating loss $10.3 million, an increase primarily due to the Oratech-related one-time expenses.
Adjusted operating loss (non-GAAP) $4.6 million, unchanged year-over-year despite lower revenue, reflecting the benefits of cost optimization initiatives.
Cash used in operating activities $3.7 million, a 33% decline compared to Q1 2025, primarily reflecting improved operational efficiencies and working capital management.
Unrestricted cash and cash equivalents $11.4 million at the end of Q1 2026 compared to $2.2 million at year-end 2025, an increase due to the $10 million financing and approximately $6.5 million of cash associated with the Oratech acquisition.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Acquisition of Oratech: Lifeward acquired Oratech, gaining access to the protein oral delivery platform, including ORMD-0801 oral insulin, which is expected to commence a Phase II study. This acquisition strengthens Lifeward's position in biomedical innovation and neurorehabilitation.
Upper body exoskeleton technology: Lifeward acquired an upper body exoskeleton technology to address the unmet needs of approximately 4.6 million stroke survivors. Development is underway for commercial launch.
ReWalk personal exoskeleton sales: Sales increased 11% year-over-year, driven by international sales, reimbursement coverage, and distribution expansion.
Expansion of reimbursement access: Broadened reimbursement access for ReWalk through Medicare Advantage insurers such as Aetna, Humana, and UnitedHealthcare.
Manufacturing transition: Completed transition from Fremont, California facility to contract manufacturing in Massachusetts, improving operational leverage.
Cost optimization: Adjusted operating expenses declined 12% year-over-year due to improved productivity, lower reimbursement-related costs, and reduced R&D spending.
Path to profitability: Secured $10 million in convertible note financing, strengthening the balance sheet and improving operating flexibility.
Strategic acquisitions: Evaluating additional strategic and accretive acquisition opportunities to complement core rehabilitation and biomedical platforms.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Supply Chain Disruptions: Temporary timing disruptions in AlterG shipments due to working capital constraints and supply chain execution issues late last year. This has impacted revenue and shipment execution.
Manufacturing Transition Challenges: Financial impacts and operational disruptions from the closure of the Fremont, California facility and the shift to contract manufacturing in Massachusetts.
Tariffs and Freight Costs: Higher freight and tariff expenses have negatively impacted gross margins.
Foreign Currency Exchange Rate Movements: Unfavorable foreign currency exchange rate movements have contributed to lower gross margins.
Revenue Decline: Year-over-year revenue decline from $5 million to $3.9 million, primarily driven by lower AlterG shipments.
One-Time Noncash R&D Expense: A $4.9 million one-time noncash research and development expense related to the Oratech acquisition has increased operating losses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Path to profitability: Lifeward expects continued operational stabilization over the next several quarters, with improved visibility as they move toward the end of 2026 and into 2027.
Commercialization and market expansion: The company is expanding distribution in the U.S. and internationally, broadening reimbursement access for ReWalk, including through Medicare Advantage insurers such as Aetna, Humana, and UnitedHealthcare. This positions the neurorehabilitation portfolio for long-term growth.
ReWalk personal exoskeleton sales: Sales increased 11% year-over-year, with expectations for continued growth driven by international sales, reimbursement, and distribution expansion.
AlterG shipments: The company has a backlog of secured AlterG orders and expects improved shipment execution during the second and third quarters of 2026.
Upper body exoskeleton technology: Development work is underway for the newly acquired technology, targeting commercial launch to address unmet needs of stroke survivors.
Strategic acquisitions: Lifeward continues to evaluate strategic and accretive acquisition opportunities to complement its core rehabilitation and biomedical platform.
Operational efficiency and cost management: Focus remains on disciplined cash management, improving operational efficiency, and positioning the business for scalable growth and long-term profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:In terms of AlterG, should we anticipate for the second and third quarter to get back to the level similar to last year and make up for the differences?
A:William Grant stated that it is a fair assumption and expects the performance to bridge across the second and third quarter.
Q:Given the lower first quarter figures this year, should we anticipate additional growth in the remaining three quarters to match up to the total revenue similar to last year?
A:William Grant explained that the lower figures were due to a manufacturing move and cash constraints, but expects similar revenue to last year with a better exit trajectory compared to the entry trajectory.
Q:Could you provide some color on ReWalk units in Germany and the United States?
A:Almog Adar reported that revenues in Germany increased almost 25% quarter-over-quarter, and total ReWalk revenues increased 11% year-over-year, ending at $1.6 million compared to $1.3 million in the prior year quarter.
Q:What is the nature of the AlterG supply/working capital issue, and do you think it will be resolved soon?
A:William Grant explained that the issues are related to cash constraints and procurement timing. He expects to resolve most issues by the end of the quarter but anticipates some will carry into the next quarter, with full resolution likely in Q3.
Q:Is there a book of sales that you can provide for the next couple of quarters?
A:William Grant stated that they are not providing forward-looking guidance but expect revenues to be similar to last year with a trajectory change as they exit the year.
Q:What caused the gross margin decline of 800 basis points?
A:Almog Adar attributed 75%-85% of the decline to fluctuations in exchange rates and tariffs, with the remainder due to production reduction absorption.
Q:Can you provide additional commentary on Medicare Advantage coverage and the conversion rate on submitted claims?
A:William Grant discussed efforts to expand payer coverage, including partnerships with Aetna, Humana, and UnitedHealthcare, and plans to push further into private placements. However, he did not provide specific data on the pipeline or conversion rates.
Q:How are you managing resources and navigating changes with the addition of new products like the upper body exoskeleton?
A:William Grant explained that the Oratech transaction does not drain resources as it is handled by Oramed. For the upper body exoskeleton, they are focusing on commercialization and working with channel partners to efficiently reach patients, leveraging his extensive experience in managing revenue cycles and payer landscapes.
Q:Review of Unclear Management Responses
A:William Grant did not provide specific data on the pipeline or conversion rates for Medicare Advantage coverage, using vague language about ongoing efforts and future plans.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Almog Adar
AlterG order
AlterG shipment
California facility
Development work
Humana UnitedHealthcare
II study
Massachusetts acquisition
MedTech takeaway
Oramed fund
Phase II
ReWalk Medicare
ReWalk exoskeleton
ReWalk platform
ReWalk term
SEC equity
UnitedHealthcare neurorehabilitation
access ReWalk
access neuro
access protein
acquisition access
acquisition opportunity
acquisition transaction
background experience
capital
core
focus neurorehabilitation
manufacturing transition
path profitability
rehabilitation platform
reimbursement
visibility
LFWD Transcript
Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
Unknown5-15
The earnings call reveals mixed signals: declining revenue and gross margin, but with optimistic guidance on revenue recovery and cash flow improvements. The company's strategic initiatives, such as international expansion and new product launches, are promising. However, the absence of forward guidance and unresolved supply chain issues are concerning. The Q&A section highlights management's confidence in overcoming current challenges, yet lacks specific guidance, creating uncertainty. Thus, the stock price is likely to remain stable, with potential for moderate fluctuations as the market digests these mixed signals.
Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call revealed a 14% revenue decline and flat exoskeleton sales, despite increased unit sales. Gross profit improved, but operating expenses and losses remain high. The Q&A section highlighted uncertainties in the company's market strategy and competitive advantage. Positive elements included narrowed net loss and reduced operating cash usage. However, weak financial performance and lack of clear competitive strategy outweigh these positives, leading to a negative sentiment.
Lifeward Ltd. (LFWD) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call highlights operational efficiencies and a strong pipeline, but concerns arise due to increased operating expenses and cash constraints. The Q&A reveals optimism in partnerships and revenue growth, yet lacks clarity on strategic execution. Despite the positive outlook, uncertainties in Medicare reliance and AlterG sales decline temper enthusiasm. The neutral rating reflects mixed signals, with potential growth balanced by financial and operational challenges.
Lifeward Ltd. (LFWD) Q2 2025 Earnings Call Transcript
Unknown8-14
Despite some positive developments, such as operational efficiencies and Medicare revenue growth, the earnings report reflects mixed signals. Revenue decline, increased GAAP operating expenses due to goodwill impairment, and lack of clear guidance on margin improvements counterbalance the positives. The Q&A further highlights concerns about tariff impacts, unclear margin improvements, and lowered guidance despite expected revenue growth. These mixed signals suggest a neutral market reaction.
LFWD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
